Tag: VEN FNC

Aippy Raises Tens of Millions of Dollars at a $250 Million Valuation to Build the Future of AI-Native Interactive Entertainment

SINGAPORE, June 2, 2026 /PRNewswire/ -- Aippy, the world's first AI-native game community developed by NADA AI, today announced that it has raised tens of...

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&DFunds to accelerate Alzheimer's and immune disease...

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsVEN FNC

SATO Oyj – Managers’ Transactions

Ajay Rajan joins Protean eGov Technologies Ltd. as Managing Director & Chief Executive Officer

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Tag: VEN FNC

Aippy Raises Tens of Millions of Dollars at a $250 Million Valuation to Build the Future of AI-Native Interactive Entertainment

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us